Figure 3 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma

figure

posted on 2025-02-19, 08:40 authored by Luiza Doro Pereira, Monica Wielgos-Bonvallet, Selim Misirlioglu, Alireza Khodadai-Jamayran, Petar Jelinic, Douglas A. Levine

IL-8 (CXCL8) is exclusively secreted in BRCA1 methylated or mutated HGSC cells after olaparib treatment but is secreted in all HRD HGSC cells after talazoparib treatment. A, OVCAR3, (B) OVCAR8, and (C) COV362 cells were treated with DMSO, 10 μmol/L veliparib, 10 μmol/L olaparib, or 2 μmol/L talazoparib for 48 hours. The supernatants were then collected, and IL-8 protein expression was analyzed by an ELISA assay. A four-parameter logistic curve fit was used to analyze these results. T tests were performed between DMSO- and the individual PARPi–treated groups. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not statistically significant.

History

ARTICLE ABSTRACT

This work highlights how different PARPis, especially talazoparib, modulate immune-related gene expression in ovarian cancer cells, independent of the cGAS-STING pathway. These findings may improve our understanding of how different PARPis affect the immune system in various genetic backgrounds.

Usage metrics

Keywords

Dna Damage And Repair Gene amplification Oncogenes & Tumor Suppressors BRCA family Ovarian Cancer Small Molecule Agents

Licence

CC BY